Laimei Pharmaceutical (300006.SZ) announced its 2022 annual results, with a net loss of 687.091 million yuan, a narrowing of 31.65%

Zhitong Finance ·  03/17 20:34

According to the Zhitong Finance App, Laimei Pharmaceutical (300006.SZ) released its 2022 annual report. The company's revenue was 885 million yuan, a decrease of 27.80% over the previous year. The net loss attributable to shareholders of listed companies was 687.091 million yuan, a year-on-year decrease of 31.65%. Net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss was $115 million, a year-on-year decrease of 16.43%. The basic loss per share was $0.0651.

The loss in performance in 2022 was mainly affected by a combination of factors such as the national collection policy and continued maintenance of large R&D investment. Influenced by the national collection policy, the sales volume and sales unit price of the company's key product, esomeprazole enteric capsules, declined further, and sales revenue and profits declined accordingly; due to logistics stoppages in some regions during the reporting period, demand for hospitalization declined, which also had a certain impact on the delivery and sales of the company's related products.

This page is machine-translated. Futubull tries to improve but do not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.

Risk disclosure: The above content only represents the opinion of the authors or guests, and does not represent any positions of Futu or constitute any investment advice on the part of Futu. Before making any investment decision, investors should consider the risk factors related to investment products based on their own circumstances and consult professional investment advisers where necessary. Futu makes every effort to verify the authenticity, accuracy, and originality of the above content, but does not make any guarantees or promises.

    Write first comment